Mark Kris, MD: Evaluating Therapeutic Options
Watch
Mark Kris, MD: Choosing a Treatment in NSCLC
Mark Kris, MD: Lacking Actionable Mutations in NSCLC
mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD: Case 2
mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD
Tanios Bekaii-Saab, MD; Chemotherapy as a Possible Option
Tara Seery, MD; Chemotherapy as a Possible Option
Tanios Bekaii-Saab, MD: KRAS Status in mCRC
Tara Seery, MD: KRAS Status in mCRC
Tanios Bekaii-Saab, MD: Impact of Third-Line Therapy
Tara Seery, MD: Impact of Third-Line Therapy
Tanios Bekaii-Saab, MD: Clinical Data Supporting Trifluradine-Tipiracil
Tara Seery, MD: Clinical Data Supporting Trifluradine-Tipiracil
Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC
Tara Seery, MD: Fourth-Line Therapy in mCRC
Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab
Charles Fuchs, MD: Strategies to Increase RAS Testing
Charles Fuchs, MD: Impeding RAS Mutation Testing
Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC
Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies
Charles Fuchs, MD: Clinical Importance of RAS Mutations
Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer
Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab
Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing
Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing
Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC
Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies
Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations
Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer
Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD
